James Farrell - Abbott Laboratories Independent Director

ABT Stock  USD 113.48  1.98  1.78%   

Director

Mr. W. James Farrell is Independent Director of the Company. Mr. Farrell served as the Chairman of Illinois Tool Works Inc. from 1996 to 2006 and as its Chief Executive Officer from 1995 to 2005. Mr. Farrell also served on the Board of Directors of 3M Company from 2006 to 2014, Allstate Insurance Company from 1999 to 2013, and UAL Corporation from 2001 to 2012. As a result of his tenure as Chairman and Chief Executive Officer of Illinois Tool Works, Mr. Farrell brings valuable business, leadership and management experience to the Board and provides guidance on key matters relevant to a major international company. since 2006.
Age 72
Tenure 18 years
Address 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400
Phone224 667 6100
Webhttps://www.abbott.com

Abbott Laboratories Management Efficiency

The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Assets are comparatively stable compared to the past year. Return On Equity is likely to gain to 0.26 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024.
The company has 15.87 B in debt with debt to equity (D/E) ratio of 0.46, which is OK given its current industry classification. Abbott Laboratories has a current ratio of 1.82, which is typical for the industry and considered as normal. Debt can assist Abbott Laboratories until it has trouble settling it off, either with new capital or with free cash flow. So, Abbott Laboratories' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abbott Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abbott to invest in growth at high rates of return. When we think about Abbott Laboratories' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Richelle ParhamLaboratory
53
Donna ShalalaMednax Inc
75
John PartridgeCigna Corp
71
Dipchand NisharGuardant Health
N/A
Samir KaulGuardant Health
44
JeanLuc BelingardLaboratory
72
Jane HenneyCigna Corp
69
TimothyCigna Corp
N/A
Kimberly RossCigna Corp
56
Mary HoeltzelCigna Corp
N/A
Mark McClellanCigna Corp
57
Garheng KongLaboratory
45
Gary GillilandLaboratory
63
James RogersCigna Corp
69
Enrique SosaMednax Inc
79
Robert WilliamsLaboratory
72
Sanders WilliamsLaboratory
69
Stanley MeresmanGuardant Health
71
Paul GabosMednax Inc
55
Robert MittelstaedtLaboratory
74
Karey BarkerMednax Inc
52
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. Abbott Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 113000 people. Abbott Laboratories (ABT) is traded on New York Stock Exchange in USA. It is located in 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400 and employs 114,000 people. Abbott Laboratories is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Abbott Laboratories Leadership Team

Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Samuel Scott, Independent Director
Christopher Scoggins, Senior Vice President - Rapid Diagnostics
Roger Bird, Senior Vice President - U.S. Nutrition
Michael Dale, Senior Vice President - Structural Heart
Sammy Karam, Senior Vice President - Established Pharmaceuticals, Emerging Markets
Heather Mason, Senior Vice President - Abbott Diabetes Care
James Farrell, Independent Director
Phebe Novakovic, Independent Director
JeanYves Pavee, Senior Vice President - Established Pharmaceuticals, Developed Markets
Roxanne Austin, Independent Director
Stephen Fussell, Executive Vice President - Human Resources
Sally Blount, Independent Director
Daniel Starks, Independent Director
Michael Pederson, Senior Vice President - Electrophysiology and Heart Failure
Thomas Frinzi, Senior Vice President - Abbott Medical Optics
Lisa Earnhardt, Executive Vice President - Medical Devices
Alejandro Wellisch, Senior Vice President - Established Pharmaceuticals, Latin America
Robert Alpern, Independent Director
Murthy Simhambhatla, Senior Vice President - Abbott Medical Optics
Glenn Tilton, Independent Director
Darren McDew, Independent Director
Christopher Calamari, Senior Vice President - U.S. Nutrition
Erica Battaglia, VP Officer
Richard Ashley, Executive VP of Corporate Devel.
Michael Rousseau, President - Cardiovascular and Neuromodulation
Charles Brynelsen, Senior Vice President - Abbott Vascular
Hubert Allen, Executive Vice President, General Counsel, Secretary
Charles Foltz, Senior Vice President - Abbott Vascular
Brian Yoor, Chief Financial Officer, Executive Vice President - Finance
Gregory Ahlberg, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Philip Boudreau, Vice President - Finance, Controller
John Ginascol, Executive Vice President - Core Diagnostics
Patricia Gonzalez, Independent Director
Jared Watkin, Senior Vice President - Diabetes Care
Brian Blaser, Executive VP of Diagnostic Products
Scott White, Senior Vice President - International Nutrition
Michael Roman, Independent Director
Deepak Nath, Senior Vice President - Abbott Vascular
Jaime Contreras, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Mary Moreland, Executive Vice President of Human Resources
Nancy McKinstry, Independent Director
Andrew Lane, Senior Vice President - Established Pharmaceuticals, Emerging Markets
Sabina Ewing, Senior Officer
Georges Vos, Senior Vice President - Established Pharmaceuticals, Emerging Markets
Thomas Freyman, Executive VP of Fin. and Admin.
Randel Woodgrift, Senior Vice President - CRM
Michelle Kumbier, Independent Director
Eric Fain, Senior Vice President Group President - Cardiovascular and Neuromodulation
John Capek, Executive Vice President - Ventures
Miles White, Chairman, CEO and Chairman of Executive Committee
Robert Ford, President, Chief Executive Officer, Chief Operating Officer, Director
Elaine Leavenworth, VP Officer
Edward Liddy, Independent Director
John Stratton, Independent Director
Joseph Manning, Senior Vice President - Abbott Nutrition International
Scott Leinenweber, Acquisitions Licensing
James Young, VP Officer
William Osborn, Lead Independent Director
Michael Warmuth, Executive Vice President - Established Pharmaceuticals
Louis Morrone, Senior Vice President - Rapid Diagnostics
Robert Funck, Chief Financial Officer, Executive Vice President - Finance
Daniel Salvadori, Senior Vice President - Established Pharmaceuticals, Latin America.
Andrea Wainer, Executive Vice President - Rapid and Molecular Diagnostics
Melissa Brotz, Vice Marketing

Abbott Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Abbott Laboratories Investors Sentiment

The influence of Abbott Laboratories' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Abbott. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Abbott Laboratories' public news can be used to forecast risks associated with an investment in Abbott. The trend in average sentiment can be used to explain how an investor holding Abbott can time the market purely based on public headlines and social activities around Abbott Laboratories. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Abbott Laboratories' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Abbott Laboratories' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Abbott Laboratories' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Abbott Laboratories.

Abbott Laboratories Implied Volatility

    
  21.49  
Abbott Laboratories' implied volatility exposes the market's sentiment of Abbott Laboratories stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Abbott Laboratories' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Abbott Laboratories stock will not fluctuate a lot when Abbott Laboratories' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Abbott Laboratories in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Abbott Laboratories' short interest history, or implied volatility extrapolated from Abbott Laboratories options trading.

Pair Trading with Abbott Laboratories

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abbott Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abbott Laboratories will appreciate offsetting losses from the drop in the long position's value.

Moving against Abbott Stock

  0.56SSY SunLink Health SystemsPairCorr
  0.47FIGS Figs Inc Financial Report 2nd of May 2024 PairCorr
  0.47TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
  0.44CVS CVS Health Corp Financial Report 1st of May 2024 PairCorr
  0.43CMAXW CareMaxPairCorr
The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.
The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Abbott Laboratories is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Abbott Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Abbott Laboratories Stock. Highlighted below are key reports to facilitate an investment decision about Abbott Laboratories Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.
Note that the Abbott Laboratories information on this page should be used as a complementary analysis to other Abbott Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Abbott Stock analysis

When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Is Abbott Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abbott Laboratories. If investors know Abbott will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abbott Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.55
Dividend Share
2.08
Earnings Share
3.26
Revenue Per Share
23.051
Quarterly Revenue Growth
0.015
The market value of Abbott Laboratories is measured differently than its book value, which is the value of Abbott that is recorded on the company's balance sheet. Investors also form their own opinion of Abbott Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Abbott Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abbott Laboratories' market value can be influenced by many factors that don't directly affect Abbott Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abbott Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abbott Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbott Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.